Objectives: In the present study we investigated the possible cardioprotective effects of GLP-1 and SGLTi against diabetic cardiomyopathy (DCM) in type 2 diabetic rats and the mechanisms underlying these effects.

Methods: 32- male Sprague Dawley rats were randomly subdivided into 4 equal groups; a) control group, b) DM group, type 2 diabetic rats received 2ml oral saline daily for 4 weeks, c) DM+ GLP-1, type 2 diabetic rats were treated with GLP-1 analogue (liraglutide) at a dose of 75 µg/kg via S.C. injection for 4 weeks and d) DM+ SGLTi: type 2 diabetic rats received SGLT2 inhibitor (dapagliflozin) at a dose of 1mg/kg via oral gastric gavage. By the end of treatment (4 weeks), serum blood glucose, HOMA-IR, insulin and cardiac enzymes (LDH, CK-MB) were measured. Also, the cardiac histopathology, myocardial oxidative stress markers (MDA, GSH and CAT) and norepinephrine (NE), myocardial fibrosis, the expression of caspase-3, TGF-β, TNF-α and tyrosine hydroxylase (TH) in myocardial tissues were measured.

Results: T2DM caused significant increase in serum glucose, HOMA-IR index, serum CK-MB and LDH (p< 0.05). This was associated with significant myocardial damage and fibrosis, elevation of myocardial MDA, NE with upregulation of myocardial caspase-3, TNF-α, TGF-β and TH and significant decrease in serum insulin and myocardial GSH and CAT (p<0.05). Administration of either GLP-1 analog or SGLTi caused in significant improvement in all studied parameters (p< 0.05).

Conclusions: GLP-1 and SGLTi exhibited cardioprotective effects against DCM in type 2 diabetic rats. SGLTi showed more cardioprotective effect than GLP-1. The cardioprotective actions of these agents might be due to attenuation of fibrosis, oxidative stress, apoptosis (caspase-3), sympathetic nerve activity and inflammatory cytokines (TNF-α and TGF-β).


E.A. Eid: None. A. Hussein: None. L. Lashin: None. M. Taha: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.